Neonatal Sulfhemoglobinemia and Hemolytic Anemia Associated With Intestinal Morganella morganii

Pediatrics. 2015 Dec;136(6):e1641-5. doi: 10.1542/peds.2015-0996. Epub 2015 Nov 9.

Abstract

Sulfhemoglobinemia is a rare disorder characterized by the presence of sulfhemoglobin in the blood. It is typically drug-induced and may cause hypoxia, end-organ damage, and death through oxygen deprivation. We present here a case of non-drug-induced sulfhemoglobinemia in a 7-day-old preterm infant complicated by hemolytic anemia. Microbiota compositional analysis of fecal samples to investigate the origin of hydrogen sulphide revealed the presence of Morganella morganii at a relative abundance of 38% of the total fecal microbiota at the time of diagnosis. M morganii was not detected in the fecal samples of 40 age-matched control preterm infants. M morganii is an opportunistic pathogen that can cause serious infection, particularly in immunocompromised hosts such as neonates. Strains of M morganii are capable of producing hydrogen sulphide, and virulence factors include the production of a diffusible α-hemolysin. The infant in this case survived intact through empirical oral and intravenous antibiotic therapy, probiotic administration, and red blood cell transfusions. This coincided with a reduction in the relative abundance of M morganii to 3%. Neonatologists should have a high index of suspicion for intestinal pathogens in cases of non-drug-induced sulfhemoglobinemia and consider empirical treatment of the intestinal microbiota in this potentially lethal condition.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Hemolytic / complications*
  • Anemia, Hemolytic / therapy
  • Enterobacteriaceae Infections / complications*
  • Enterobacteriaceae Infections / microbiology
  • Enterobacteriaceae Infections / therapy
  • Feces / microbiology
  • Female
  • Gastrointestinal Microbiome
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Morganella morganii*
  • Sulfhemoglobinemia / complications*
  • Sulfhemoglobinemia / therapy